| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Booth Andrew is a Chief Financial Officer at ABCL. Recent filings cover 5 purchases and 1 sale. Those positions are worth an estimated $5.8M at current prices.
Our model assigns Booth Andrew a below-average insider score of 43/100, based on 4 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -0.7%.
Booth Andrew's largest disclosed position is in ABCL as Chief Financial Officer, worth about $5.8M. The recent filings there lean toward selling, a net 995,800 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Buy | 37,200 | $10.32 | $383,904.00 | +8.3% | - | - | |
| May 26, 2023 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Buy | 14,500 | $6.85 | $99,325.00 | +10.5% | -19.1% | -43.4% | |
| May 12, 2022 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Buy | 85,000 | $5.79 | $492,150.00 | +158.9% | +98.8% | -14.5% | |
| Nov 11, 2021 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Buy | 67,500 | $14.71 | $993,130.00 | +57.7% | -35.7% | -9.8% | |
| Jun 9, 2021 | ABCL Abcellera Biologics Inc. | Chief Financial Officer | Sell | 1,200,000 | $25.50 | $30,600,000.00 | -100% | -20.5% | -64.8% |